Fuda Cancer Hospital
Stomach cancer stage 2 treatment cost in China typically depends on surgical complexity and medication protocols. Primary procedures like stomach cancer surgery run from $18,500 to $34,500, while a stomach resection ranges from $18,500 to $36,500. Total expenses are influenced by hospital grade, medication types, and the city. International patients can save 40-60% compared to the US. Top treatment hubs include Guangzhou, Beijing, and Shanghai.
Typical Stomach Cancer Stage 2 Treatment Costs in China
Bookimed Expert Insight: Patients seeking alternatives to systemic chemotherapy should consider specialized centers like Fuda Cancer Hospital. This Joint Commission International (JCI) accredited facility focuses on minimally invasive oncology. They apply over 10 types of local therapies, including cryosurgery and NanoKnife. This approach is highly effective for patients requiring targeted treatment. Specialists like Song Shijun provide expertise within a multidisciplinary team serving over 30,000 international patients.
| China | Turkey | Austria | |
| Stomach resection | from $18,500 | from $16,470 | from $22,000 |
| Stomach cancer surgery | from $18,500 | from $22,320 | from $30,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Stomach cancer stage 2 treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stomach cancer stage 2 treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stomach cancer stage 2 treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
The standard surgical procedure for Stage 2 stomach cancer in China is radical gastrectomy combined with D2 lymphadenectomy. Surgeons perform either subtotal or total stomach removal based on tumor location. This procedure follows Chinese Society of Clinical Oncology guidelines to ensure complete tumor clearance and extensive lymph node harvest.
Bookimed Expert Insight: Chinese oncology centers demonstrate a high capacity for complex cases, with Fuda Cancer Hospital serving over 30,000 international patients. Clinical patterns show that centers in Guangzhou and Xiamen prioritize multidisciplinary teams. These teams often integrate cryosurgery or NanoKnife technologies for cases where traditional surgery requires additional local control.
Patient Consensus: Patients emphasize that final pathology reports after surgery often lead to adjustments in the treatment plan. They note it is vital to prepare for significant dietary changes and nutritional adaptation following a total gastrectomy.
Chemotherapy is common for stage 2 stomach cancer but not always mandatory after surgery. Neoadjuvant chemotherapy before surgery is standard for shrinking tumors to improve resection success. Adjuvant chemotherapy after surgery eliminates microscopic cells. The decision depends on lymph node status and tumor depth found during resection.
Bookimed Expert Insight: Patient data suggests that recovery speed often dictates the chemotherapy timeline. Fuda Cancer Hospital serves over 30,000 international patients and focuses on minimally invasive alternatives. If postoperative weight loss is severe, doctors may prioritize recovery before starting heavy drug cycles to ensure patient safety.
Patient Consensus: Patients note that stage 2 treatment plans vary. Some undergo surgery first while others start with chemo to control tumor spread. Many emphasize that post-surgical eating difficulties can make starting chemotherapy challenging.
Chinese hospitals primarily prescribe fluoropyrimidine and platinum-based doublet therapies for Stage 2 stomach cancer. The Chinese Society for Clinical Oncology guidelines recommend these after D2 gastrectomy. Standard regimens include SOX, XELOX, and FOLFOX. These protocols reduce recurrence risks and target microscopic spread.
Bookimed Expert Insight: Clinical practice in China shows a strong preference for the SOX regimen. It is more common here than in Western countries. This is because S-1 is specifically effective in East Asian populations. Patients should ensure their nutritional status is stable. Doctors at clinics like Fuda Cancer Hospital adjust doses based on body weight. This flexibility helps patients complete the full course safely.
Patient Consensus: Patients note that doctors prioritize oxaliplatin-based doublets as the modern standard. Many emphasize that dose adjustments or treatment delays are routine to manage nutrition and lab values.
International patients at top Chinese oncology centers typically see 5-year survival rates between 63% and 86% for Stage 2 stomach cancer. These rates reflect outcomes from high-volume urban institutions. Success depends on radical D2 gastrectomy and adjuvant chemotherapy. Advanced molecular profiling further improves these benchmarks.
Bookimed Expert Insight: Survival data in China is heavily influenced by surgical specialization. Facilities like Fuda Cancer Hospital have served over 30,000 patients from 100 countries. This massive volume often leads to better outcomes in complex D2 lymphadenectomies. Patients should prioritize hospitals with JCI accreditation to ensure international pathology and safety standards are met.
Patient Consensus: Patients note that survival depends on achieving clear surgical margins and adequate lymph node removal. Many emphasize that long-term recovery requires proactive management of nutrition, B12 levels, and post-operative weight loss.
International patients usually stay in China for 3 to 6 months for complete Stage 2 stomach cancer treatment. This period covers specialized surgery like radical D2 gastrectomy and multiple rounds of adjuvant chemotherapy. JCI-accredited facilities in cities like Guangzhou provide these integrated oncology protocols.
Bookimed Expert Insight: Patients can optimize their stay by choosing clinics like Fuda Cancer Hospital. This facility specializes in minimally invasive therapies that may serve as alternatives to traditional chemotherapy. Their experience with over 30,000 international patients ensures streamlined transitions between surgical recovery and local outpatient lodging.
Patient Consensus: Patients emphasize that recovery is measured in weeks rather than days. They recommend staying near the hospital after discharge to manage feeding issues or nutrition adjustments before flying home.
Chinese centers integrate Traditional Chinese Medicine (TCM) into Stage 2 stomach cancer protocols as supportive care. Major hospitals alongside Western oncology departments provide TCM to manage side effects. It never replaces the primary curative strategy of radical gastrectomy and adjuvant chemotherapy in JCI-accredited facilities.
Bookimed Expert Insight: While many search for alternative cures, Chinese oncology centers like Fuda Cancer Hospital emphasize a multidisciplinary approach. They combine Western surgery with advanced technologies like cryosurgery or NanoKnife rather than TCM alone. Our data shows these integrated centers favor TCM specifically for post-operative recovery blocks to help patients tolerate intensive chemotherapy.
Patient Consensus: Patients note that TCM is most effective for regaining their appetite and bowels after major stomach surgery. They often warn others to ensure that herbal therapies do not delay the necessary surgical staging or chemotherapy schedule.
Immunotherapy and targeted agents are not standard for Stage 2 stomach cancer in China. Most Chinese clinical protocols prioritize radical D2 surgery and cytotoxic chemotherapy. These advanced therapies are typically reserved for Stage 4 metastatic disease or specifically documented recurrence cases.
Bookimed Expert Insight: While Stage 2 standard care is surgery-focused, specialized centers like Fuda Cancer Hospital utilize over 10 types of minimally invasive therapies. These technologies, including NanoKnife and cryosurgery, provide localized alternatives to systemic drugs. This is particularly valuable for patients who cannot tolerate aggressive chemotherapy after their gastrectomy.
Patient Consensus: Patients note that D2 surgery is the expected first step. Many emphasize asking for biomarker tests early to identify long-term options if the cancer recurs.